马应龙：子公司获得药品注册证书

Group 1 - The core point of the article is that Mayinglong (600993) announced that its subsidiary, Jiangxi Mayinglong Meikang Pharmaceutical Co., Ltd., has received the drug registration certificate for Olozoline Hydrochloride Eye Drops from the National Medical Products Administration [1] Group 2 - The approval of the drug registration certificate indicates a significant regulatory milestone for the company, potentially enhancing its product portfolio in the ophthalmic medication market [1] - This development may lead to increased revenue opportunities for the company as it expands its offerings in the pharmaceutical sector [1] - The approval reflects the company's ongoing commitment to innovation and compliance with regulatory standards in the healthcare industry [1]